PMID- 36620537 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230302 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer. PG - 1015264 LID - 10.3389/fonc.2022.1015264 [doi] LID - 1015264 AB - INTRODUCTION: Stereotactic Body Radiation Therapy (SBRT) has emerged as a definitive therapy for localized prostate cancer (PCa). However, more data is needed to predict patient prognosis to help guide which patients will benefit most from treatment. The FACIT-Fatigue (FACIT-F) is a well validated, widely used survey for assessing fatigue. However, the role of fatigue in predicting PCa survival has yet to be studied. Herein, we investigate the role of FACIT-F as a baseline predictor for overall survival (OS) in patients undergoing SBRT for localized PCa. METHODS: A retrospective review was conducted of 1358 patients who received SBRT monotherapy between January 2008 to April 2021 at an academic, tertiary referral center. FACIT-F scores (range 0 to 52) were summed for patients who answered all 13-items on the survey. FACIT-F total scores of >/=35 represented severe fatigue. Patients receiving androgen deprivation therapy were excluded. Differences in fatigue groups were evaluated using chi-squared tests. OS rates were determined using the Kaplan-Meier method and predictors of OS were evaluated using Cox proportional hazard method. RESULTS: Baseline full FACIT-F scores and survival data was available for 891 patients. 5-year OS was 87.6% and 95.2%, respectively, for the severely fatigued and non-fatigued groups. Chi-squared analysis of fatigue groups showed no significant difference in the following categories: D'Amico risk group, age, ethnicity, grade group, T-stage, or PSA density. Severe fatigue was associated with a significant decrease in OS (hazard ratio 2.76; 95%CI 1.55 - 4.89). The Cox proportional hazard model revealed that age and FACIT-F were both statistically significant (p <0.05). CONCLUSION: Baseline FACIT-F scores are significantly associated with OS. Higher FACIT-F scores, representing less fatigued patients, are associated with an overall survival benefit. These results indicate that the FACIT-F survey could serve as an additional metric for clinicians in determining prognostic factors for patients undergoing SBRT. CI - Copyright (c) 2022 Simhal, Sholklapper, Simhal, Zwart, Danner, Kumar, Aghdam, Suy, Hankins, Kowalczyk and Collins. FAU - Simhal, Rishabh K AU - Simhal RK AD - School of Medicine, Georgetown University, Washington, DC, United States. FAU - Sholklapper, Tamir N AU - Sholklapper TN AD - School of Medicine, Georgetown University, Washington, DC, United States. FAU - Simhal, Anish K AU - Simhal AK AD - Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, United States. FAU - Zwart, Alan L AU - Zwart AL AD - Department of Radiation Oncology, MedStar Georgetown University Hospital, Washington, DC, United States. FAU - Danner, Malika T AU - Danner MT AD - Department of Radiation Oncology, MedStar Georgetown University Hospital, Washington, DC, United States. FAU - Kumar, Deepak AU - Kumar D AD - Julius L. Chambers Research Institute, North Carolina Central University, Durham, NC, United States. FAU - Aghdam, Nima AU - Aghdam N AD - Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States. FAU - Suy, Simeng AU - Suy S AD - Department of Radiation Oncology, MedStar Georgetown University Hospital, Washington, DC, United States. FAU - Hankins, Ryan A AU - Hankins RA AD - School of Medicine, Georgetown University, Washington, DC, United States. AD - Department of Urology, MedStar Georgetown University Hospital, Washington, DC, United States. FAU - Kowalczyk, Keith J AU - Kowalczyk KJ AD - School of Medicine, Georgetown University, Washington, DC, United States. AD - Department of Urology, MedStar Georgetown University Hospital, Washington, DC, United States. FAU - Collins, Sean P AU - Collins SP AD - School of Medicine, Georgetown University, Washington, DC, United States. AD - Department of Radiation Oncology, MedStar Georgetown University Hospital, Washington, DC, United States. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20221223 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9816795 OTO - NOTNLM OT - SBRT (stereotactic body radiation therapy) OT - baseline fatigue OT - localized prostate cancer (PCa) OT - overall survival OT - prostate cancer OT - prostate radiation therapy OT - quality of life OT - urology COIS- SC is a consultant for Accuray, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/10 06:00 MHDA- 2023/01/10 06:01 PMCR- 2022/01/01 CRDT- 2023/01/09 04:14 PHST- 2022/08/09 00:00 [received] PHST- 2022/11/21 00:00 [accepted] PHST- 2023/01/09 04:14 [entrez] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/10 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.1015264 [doi] PST - epublish SO - Front Oncol. 2022 Dec 23;12:1015264. doi: 10.3389/fonc.2022.1015264. eCollection 2022.